146 related articles for article (PubMed ID: 37661636)
1. Therapeutic targeting of microtubule affinity-regulating kinase 4 in cancer and neurodegenerative diseases.
Alam M; Ahmed S; Abid M; Hasan GM; Islam A; Hassan MI
J Cell Biochem; 2023 Sep; 124(9):1223-1240. PubMed ID: 37661636
[TBL] [Abstract][Full Text] [Related]
2. Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy.
Anwar S; Shahwan M; Hasan GM; Islam A; Hassan MI
Cell Signal; 2022 Nov; 99():110434. PubMed ID: 35961526
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pyrazolopyrimidine derivatives as microtubule affinity regulating kinase 4 inhibitors: Towards therapeutic management of Alzheimer's disease.
Naqvi AAT; Jairajpuri DS; Noman OMA; Hussain A; Islam A; Ahmad F; Alajmi MF; Hassan MI
J Biomol Struct Dyn; 2020 Aug; 38(13):3892-3907. PubMed ID: 31512980
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Microtubule Affinity Regulating Kinase 4 by Metformin: Exploring the Neuroprotective Potential of Antidiabetic Drug through Spectroscopic and Computational Approaches.
Ashraf GM; DasGupta D; Alam MZ; Baeesa SS; Alghamdi BS; Anwar F; Alqurashi TMA; Sharaf SE; Al Abdulmonem W; Alyousef MA; Alhumaydhi FA; Shamsi A
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889524
[TBL] [Abstract][Full Text] [Related]
5. Targeting inhibition of microtubule affinity regulating kinase 4 by Harmaline: Strategy to combat Alzheimer's disease.
Adnan M; Anwar S; DasGupta D; Patel M; Elasbali AM; Alhassan HH; Shafie A; Siddiqui AJ; Bardakci F; Snoussi M; Hassan MI
Int J Biol Macromol; 2023 Jan; 224():188-195. PubMed ID: 36257368
[TBL] [Abstract][Full Text] [Related]
6. Microtubule affinity-regulating kinase 4 with an Alzheimer's disease-related mutation promotes tau accumulation and exacerbates neurodegeneration.
Oba T; Saito T; Asada A; Shimizu S; Iijima KM; Ando K
J Biol Chem; 2020 Dec; 295(50):17138-17147. PubMed ID: 33020179
[TBL] [Abstract][Full Text] [Related]
7. Investigating MARK4 inhibitory potential of Bacopaside II: Targeting Alzheimer's disease.
Anwar S; Mohammad T; Azhar MK; Fatima H; Alam A; Hasan GM; Islam A; Kaur P; Hassan MI
Int J Biol Macromol; 2023 Aug; 245():125364. PubMed ID: 37315665
[TBL] [Abstract][Full Text] [Related]
8. Structural and biochemical investigation of MARK4 inhibitory potential of cholic acid: Towards therapeutic implications in neurodegenerative diseases.
Anwar S; Shamsi A; Kar RK; Queen A; Islam A; Ahmad F; Hassan MI
Int J Biol Macromol; 2020 Oct; 161():596-604. PubMed ID: 32535203
[TBL] [Abstract][Full Text] [Related]
9. MAP/Microtubule Affinity Regulating Kinase 4 Inhibitory Potential of Irisin: A New Therapeutic Strategy to Combat Cancer and Alzheimer's Disease.
Waseem R; Anwar S; Khan S; Shamsi A; Hassan MI; Anjum F; Shafie A; Islam A; Yadav DK
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681645
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of MARK4 by serotonin as an attractive therapeutic approach to combat Alzheimer's disease and neuroinflammation.
Shamsi A; DasGupta D; Alhumaydhi FA; Khan MS; Alsagaby SA; Al Abdulmonem W; Hassan MI; Yadav DK
RSC Med Chem; 2022 Jun; 13(6):737-745. PubMed ID: 35814926
[TBL] [Abstract][Full Text] [Related]
11. Cdk5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262.
Saito T; Oba T; Shimizu S; Asada A; Iijima KM; Ando K
Hum Mol Genet; 2019 Sep; 28(18):3062-3071. PubMed ID: 31174206
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of microtubule affinity regulating kinase 4 by an acetylcholinesterase inhibitor, Huperzine A: Computational and experimental approaches.
Alrouji M; DasGupta D; Ashraf GM; Bilgrami AL; Alhumaydhi FA; Al Abdulmonem W; Shahwan M; Alsayari A; Atiya A; Shamsi A
Int J Biol Macromol; 2023 Apr; 235():123831. PubMed ID: 36870649
[TBL] [Abstract][Full Text] [Related]
13. MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes.
Trinczek B; Brajenovic M; Ebneth A; Drewes G
J Biol Chem; 2004 Feb; 279(7):5915-23. PubMed ID: 14594945
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer's disease.
Adnan M; DasGupta D; Anwar S; Shamsi A; Siddiqui AJ; Snoussi M; Bardakci F; Patel M; Hassan MI
Front Pharmacol; 2023; 14():1276179. PubMed ID: 37795023
[No Abstract] [Full Text] [Related]
15. An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry.
Hruba L; Polishchuk P; Das V; Hajduch M; Dzubak P
Biomed Pharmacother; 2022 Feb; 146():112549. PubMed ID: 34923338
[TBL] [Abstract][Full Text] [Related]
16. Structure-based investigation of MARK4 inhibitory potential of Naringenin for therapeutic management of cancer and neurodegenerative diseases.
Anwar S; Khan S; Shamsi A; Anjum F; Shafie A; Islam A; Ahmad F; Hassan MI
J Cell Biochem; 2021 Oct; 122(10):1445-1459. PubMed ID: 34121218
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin and Empagliflozin Inhibit Microtubule Affinity Regulatory Kinase 4: Repurposing Anti-Diabetic Drugs in Neurodegenerative Disorders Using In Silico and In Vitro Approaches.
Atiya A; Das Gupta D; Alsayari A; Alrouji M; Alotaibi A; Sharaf SE; Abdulmonem WA; Alorfi NM; Abdullah KM; Shamsi A
ACS Omega; 2023 Feb; 8(7):6423-6430. PubMed ID: 36844587
[TBL] [Abstract][Full Text] [Related]
18. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
[TBL] [Abstract][Full Text] [Related]
19. PKR-inhibitor binds efficiently with human microtubule affinity-regulating kinase 4.
Naz F; Shahbaaz M; Khan S; Bisetty K; Islam A; Ahmad F; Hassan MI
J Mol Graph Model; 2015 Nov; 62():245-252. PubMed ID: 26519933
[TBL] [Abstract][Full Text] [Related]
20. Role of MARK2 in the nervous system and cancer.
Lei Y; Zhang R; Cai F
Cancer Gene Ther; 2024 Apr; 31(4):497-506. PubMed ID: 38302729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
